Among these therapeutic agents, the anti-VEGF antibody drugs, ranibizumab (Lucentis, Genentech, South San Francisco, CA), bevacizumab (Avastin, Genentech), and aflibercept (Eylea, Bayer HealthCare, Berlin, Germany) are most widely used to treat AMD in the clinical setting, and have similar efficacy and side effects [4]–[6]. This evidence concerns the gene VEGFA and age-related macular degeneration.